WO2010047361A1 - 腸管吸収性を改善する医薬組成物 - Google Patents
腸管吸収性を改善する医薬組成物 Download PDFInfo
- Publication number
- WO2010047361A1 WO2010047361A1 PCT/JP2009/068164 JP2009068164W WO2010047361A1 WO 2010047361 A1 WO2010047361 A1 WO 2010047361A1 JP 2009068164 W JP2009068164 W JP 2009068164W WO 2010047361 A1 WO2010047361 A1 WO 2010047361A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- adamantyl
- ethyl
- pyridyl
- propyl
- Prior art date
Links
- 0 C*(*)C(N**)=* Chemical compound C*(*)C(N**)=* 0.000 description 1
- QDYISHPTUNJPHS-UHFFFAOYSA-N CCCCCN(CCC1(CC(C2)C3)CC3CC2C1)C(NCC(C)Cc1ccncc1)=O Chemical compound CCCCCN(CCC1(CC(C2)C3)CC3CC2C1)C(NCC(C)Cc1ccncc1)=O QDYISHPTUNJPHS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising (a) a compound represented by the following general formula [1] or a salt thereof (hereinafter collectively referred to as “the present compound”), and (b) a lipophilic substance.
- the present compound a compound represented by the following general formula [1] or a salt thereof (hereinafter collectively referred to as “the present compound”), and (b) a lipophilic substance.
- A represents — (NR 4 ) —, — (CR 5 R 6 ) — or —O—;
- An alkylene group or an alkenylene group, which may contain, the alkylene group and the alkenylene group may be substituted with a hydroxy group, an alkoxy group, an aryl group, a siloxy group or a saturated or unsaturated heterocycle
- a and R 1 may be a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a hydroxy group or an amino group
- the alkyl group, alkenyl Group, alkynyl group, cycloalkyl group and cycloalkenyl group are halogen atom, hydroxy group, amino group, cycloalkyl group, aryl group, carboxyl group, alkoxycarbonyl group, aminocarbonyl group, adamantyl group, aryloxycarbonyl group, cyano group Substituted by a group or a saturated or unsaturated
- R 2 may be substituted with an alkyl group substituted with a carbonyl group, a halogenoalkoxycarbonyl group, an unsaturated heterocycle or an unsaturated heterocycle;
- R 2 is an adamantylalkyl group, an adamantyloxyalkyl group, an adamantylaminoalkyl group or It indicates adamantyl aminocarbonyl alkyl group;
- R 3 represents a heterocyclic unsaturated ring;
- R 4 is a hydrogen atom, an alkyl group, adamantyl group, carboxyalkyl group, an alkoxycarbonyl group, an alkoxycarbonylalkyl group, an amino group, alkyl An amino group, an acylamino group or an alkoxycarbonylamino group;
- R 5 and R 6 are the same or different and represent a hydrogen atom, an alkyl group, an amino group or an alkoxycarbonylamino group;
- Patent Document 1 This compound is disclosed in Patent Document 1 together with its production method, and has TNF- ⁇ (Tumor Necrosis Factor- ⁇ : tumor necrosis factor) production inhibitory activity. Therefore, it has been suggested that this compound can be a therapeutic agent for autoimmune diseases such as rheumatoid arthritis, allergy and diabetes (Patent Document 1).
- TNF- ⁇ Tumor Necrosis Factor- ⁇ : tumor necrosis factor
- this compound has an angiogenesis inhibitory action, such as diabetic retinopathy, retinopathy of prematurity, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis It has been suggested that it can be a therapeutic agent for corneal neovascular disease (Patent Document 2). Furthermore, it has been suggested that this compound can be a therapeutic agent for osteoporosis, osteoarthritis, respiratory diseases, skin diseases, neurodegenerative diseases and the like (Patent Documents 3 to 7). As described above, this compound is a clinically extremely useful compound.
- angiogenesis inhibitory action such as diabetic retinopathy, retinopathy of prematurity, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis It has been suggested that it can be a therapeutic agent for cornea
- an object of the present invention is to provide a pharmaceutical composition that improves the intestinal absorbability of the present compound.
- the present inventor conducted intensive studies to search for a pharmaceutical composition that improves the intestinal absorbability of the compound, and found that the intestinal absorbability is improved by dissolving the compound in a lipophilic substance. It was.
- the present invention is a pharmaceutical composition
- a pharmaceutical composition comprising (a) a compound represented by the following general formula [1] or a salt thereof, and (b) a lipophilic substance.
- A represents — (NR 4 ) —, — (CR 5 R 6 ) — or —O—;
- An alkylene group or an alkenylene group, which may contain, the alkylene group and the alkenylene group may be substituted with a hydroxy group, an alkoxy group, an aryl group, a siloxy group or a saturated or unsaturated heterocycle
- a and R 1 may be a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a hydroxy group or an amino group
- the alkyl group, alkenyl Group, alkynyl group, cycloalkyl group and cycloalkenyl group are halogen atom, hydroxy group, amino group, cycloalkyl group, aryl group, carboxyl group, alkoxycarbonyl group, aminocarbonyl group, adamantyl group, aryloxycarbonyl group, cyano group Substituted by a group or a saturated or unsaturated
- R 2 may be substituted with an alkyl group substituted with a carbonyl group, a halogenoalkoxycarbonyl group, an unsaturated heterocycle or an unsaturated heterocycle;
- R 2 is an adamantylalkyl group, an adamantyloxyalkyl group, an adamantylaminoalkyl group or It indicates adamantyl aminocarbonyl alkyl group;
- R 3 represents a heterocyclic unsaturated ring;
- R 4 is a hydrogen atom, an alkyl group, adamantyl group, carboxyalkyl group, an alkoxycarbonyl group, an alkoxycarbonylalkyl group, an amino group, alkyl An amino group, an acylamino group or an alkoxycarbonylamino group;
- R 5 and R 6 are the same or different and represent a hydrogen atom, an alkyl group, an amino group or an alkoxycarbonylamino group;
- Another aspect of the present invention is a pharmaceutical composition containing (a) the present compound and (b) a propylene glycol fatty acid ester and / or a glycerin fatty acid ester.
- the other aspect of this invention is a pharmaceutical composition containing (a) this compound, (b) propylene glycol fatty acid ester and / or glycerol fatty acid ester, and (c) solubilizer and / or surfactant. is there.
- the present invention provides a pharmaceutical composition that improves the intestinal absorbability of the present compound.
- An alkylene group is a methylene group, ethylene group, trimethylene group, propylene group, tetramethylene group, pentamethylene group, hexamethylene group, octamethylene group, decamethylene group, dodecamethylene group, methylmethylene group, ethylethylene group, dimethylethylene group.
- a straight-chain or branched alkylene group having 12 carbon atoms is shown.
- alkenylene group has 2 to 12 carbon atoms having one or more double bonds such as vinylene group, propenylene group, butenylene group, pentenylene group, hexenylene group, octenylene group, butanediylidene group, and methylpropenylene group.
- Alkyl groups are methyl, ethyl, propyl, butyl, pentyl, hexyl, octyl, decyl, dodecyl, isopropyl, isobutyl, isopentyl, isohexyl, isooctyl, t-butyl.
- the alkoxy group has 1 to 12 carbon atoms such as methoxy group, ethoxy group, propoxy group, butoxy group, hexyloxy group, octyloxy group, decyloxy group, dodecyloxy group, isopropoxy group and t-butoxy group.
- a linear or branched alkoxy group is shown.
- Alkenyl groups are vinyl, 1-propenyl, allyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4 -Represents a straight-chain or branched alkenyl group having 2 to 12 carbon atoms, such as a pentenyl group and a 5-hexenyl group.
- the alkynyl group refers to a linear or branched alkynyl group having 2 to 12 carbon atoms such as ethynyl group, propynyl group, butynyl group.
- the cycloalkyl group refers to a cycloalkyl group having 3 to 20 carbon atoms such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, cyclodecyl group, cyclododecyl group and the like.
- the cycloalkenyl group refers to a cycloalkenyl group having 5 to 20 carbon atoms such as a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group.
- the aryl group represents an aromatic hydrocarbon ring such as a phenyl group or a naphthyl group, which may have one or more substituents.
- substituents include an alkyl group, a cycloalkyl group, a carboxy group, Amino group, hydroxy group, aminoalkyl group, hydroxyalkyl group, nitro group, cyano group, halogen atom, alkyloxy group and the like can be mentioned.
- the siloxy group refers to a silicon-containing organic group such as a trialkylsilyloxy group, a dialkyl (aryl) silyloxy group, an alkyl (diaryl) oxy group, or a triarylsilyloxy group.
- Acyl group means a hydrocarbonyl group, an alkylcarbonyl group, a cycloalkylcarbonyl group, an arylcarbonyl group or a heterocyclic carbonyl group. Specific examples include a formyl group that is a hydrocarbonyl group; an acetyl group that is an alkylcarbonyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an isovaleryl group, a pivaloyl group, a monochloroacetyl group, a trifluoroacetyl group, and the like; Cyclopentylcarbonyl group and cyclohexylcarbonyl group which are carbonyl groups; benzoyl group, naphthoyl group and toluoyl group which are arylcarbonyl groups; furoyl group which is a heterocyclic carbonyl group, thenoyl group, picolinoyl group,
- the halogen atom means fluorine, chlorine, bromine or iodine.
- the heterocycle is, for example, a 5- to 20-membered saturated or unsaturated monocyclic heterocycle or bicyclic heterocycle containing 1 to 4 atoms selected from a nitrogen atom, an oxygen atom or a sulfur atom.
- These heterocyclic rings may have one or more substituents, and examples of the substituent include an alkyl group, a cycloalkyl group, a carboxy group, an amino group, a hydroxy group, an aminoalkyl group, and a hydroxyalkyl group. Nitro group, cyano group, halogen atom, alkyloxy group, aryl group, arylalkyl group, saturated or unsaturated heterocyclic ring, and the like. Further, when the above heterocyclic ring has a nitrogen atom or a sulfur atom in the ring, these atoms may be oxidized to form N-oxide, S-oxide or the like.
- saturated heterocyclic ring examples include pyrrolidine, piperidine, homopiperidine or piperazine having a nitrogen atom in the ring, morpholine having a nitrogen atom and an oxygen atom in the ring, and thiomorpholine having a nitrogen atom and a sulfur atom in the ring. And may be condensed with a benzene ring or the like to form a bicyclic heterocycle such as tetrahydroquinoline or tetrahydroisoquinoline.
- the unsaturated heterocyclic ring include monocyclic heterocyclic rings such as pyrrole, pyridine, pyrazole, imidazole, pyrazine, pyridazine, and pyrimidine having a nitrogen atom in the ring, or indole, quinoline, isoquinoline, benzimidazole, naphthyridine, Bicyclic heterocycles such as pyrrolopyridine and imidazopyridine; monocyclic heterocycles such as furan having an oxygen atom in the ring or bicyclic heterocycles such as benzofuran; single units such as thiophene having a sulfur atom in the ring Cyclic heterocycles or bicyclic heterocycles such as benzothiophene; monocyclic heterocycles such as oxazole, isoxazole, thiazole, isothiazole, etc.
- monocyclic heterocyclic rings such as pyrrole, pyridine, pyrazole, imidazole
- the unsaturated heterocyclic ring may partially include a saturated bond.
- the salt in the present invention is not particularly limited as long as it is a pharmaceutically acceptable salt, such as a salt with an inorganic acid such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, acetic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, etc.
- examples thereof include salts with organic acids, salts with alkali metals such as sodium, potassium and calcium, or alkaline earth metals.
- the quaternary ammonium salt of this compound is also included by the salt in this invention.
- geometric isomers or optical isomers are present in the present compound, these isomers are also included in the scope of the present invention.
- this compound may take the form of the hydrate and the solvate.
- Preferred examples of the present compound include the following.
- R 3 A pyridine ring.
- each group defined by the general formula [1] consists of the following groups is more preferable.
- An alkylene group or alkenylene group which may contain R 1 : an alkyl group or an alkenyl group, wherein the alkyl group and alkenyl group may be substituted with a halogen atom or an amino group, and the amino group is an alkyl group, an acyl group, an alkoxycarbonyl group or a cycloalkyloxy group Optionally substituted with a carbonyl group, R 2 : an adamantylalkyl group, R 3 : a pyridine ring, R 4 : a hydrogen atom, R 5 and R 6 : a hydrogen atom, X: oxygen atom, n: 1.
- each group defined by the general formula [1] is the following group or a salt thereof is particularly preferable.
- A —NH— or a methylene group
- B Propylene group, 1-methylpropane-1,3-diyl group, 2-methylpropane-1,3-diyl group, —CH 2 —S—CH 2 —, —S—CH 2 CH 2 —, butane— 1,4-diyl group, vinylene group, propene-1,3-diyl group or
- R 1 an ethyl group, a propyl group, a butyl group, a pentyl group, a vinyl group, a 1-propenyl group, an allyl group, a 1-butenyl group, a 2-butenyl group, 3- A butenyl group, a 1-pentenyl group, a 2-pentenyl group, a 3-pentenyl group, a 4-pentenyl group, and the amino group may be substituted with a methyl group and / or a t-butoxycarbonyl group.
- R 2 an adamantylethyl group or an adamantylpropyl group
- R 3 a pyridine ring
- X oxygen atom.
- Preferred examples of the present compound include the following compounds and salts thereof.
- Compound A 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (hereinafter also referred to as “Compound A”).
- the present compound can be produced, for example, by the method described in JP-A No. 2002-53555.
- Examples of the lipophilic substance in the present invention include fatty acids, fatty acid salts, esters of fatty acids and monohydric alcohols, and esters of fatty acids and polyhydric alcohols.
- they are widely present in the natural animal and plant world as one component such as fats and oils and lipids, and natural fats and oils containing these can also be mentioned as the lipophilic substances in the present invention.
- fatty acids fatty acid salts, esters of fatty acids and monohydric alcohols, esters of fatty acids and polyhydric alcohols, and natural oils and fats containing these will be described as lipophilic substances in the present invention.
- Fatty acid refers to a saturated or unsaturated medium chain fatty acid having 6 to 13 carbon atoms and a saturated or unsaturated long chain fatty acid having 14 to 22 carbon atoms.
- fatty acids include caproic acid, enanthic acid, caprylic acid, isooctanoic acid, pelargonic acid, capric acid, dimethyloctanoic acid, neodecanoic acid, undecanoic acid (undecylic acid), undecylenic acid, lauric acid, etc.
- myristic acid pentadecanoic acid, palmitic acid, palmitoleic acid, margaric acid (margaric acid), stearic acid, isostearic acid, oleic acid, linoleic acid, linolenic acid, ricinoleic acid, nonadecanoic acid, Examples include eicosenoic acid, arachidonic acid, and behenic acid.
- the fatty acid salt means an alkali metal salt (sodium salt, potassium salt, etc.) or an alkaline earth metal salt (magnesium salt, calcium salt, etc.) of the above fatty acid.
- alkali metal salt sodium salt, potassium salt, etc.
- alkaline earth metal salt magnesium salt, calcium salt, etc.
- fatty acid salts include sodium caproate, sodium caprylate, sodium myristate, sodium palmitate and the like.
- Esters of fatty acids and monohydric alcohols include the above fatty acids and methanol, ethanol, isopropanol, butanol, hexyl alcohol, decyl alcohol, cetyl alcohol, isocetyl alcohol, oleyl alcohol, octyldodecyl alcohol, isostearyl alcohol, hexyl decyl alcohol, etc.
- An ester with a monohydric alcohol include the above fatty acids and methanol, ethanol, isopropanol, butanol, hexyl alcohol, decyl alcohol, cetyl alcohol, isocetyl alcohol, oleyl alcohol, octyldodecyl alcohol, isostearyl alcohol, hexyl decyl alcohol, etc.
- An ester with a monohydric alcohol include the above fatty acids and methanol, ethanol, isopropanol, butanol, hexyl alcohol, decy
- esters of the above fatty acids and monohydric alcohols include ethyl linoleate, ethyl oleate, isopropyl myristate, isopropyl palmitate, isopropyl isostearate, isopropyl linoleate, butyl myristate, butyl stearate, hexyl laurate, Examples include decyl oleate, cetyl isooctanoate, isocetyl myristate, isocetyl isostearate, oleyl oleate, octyldodecyl myristate, octyldodecyl neodecanoate, isostearyl palmitate, hexyldecyl dimethyloctanoate, and the like.
- An ester of a fatty acid and a polyhydric alcohol refers to an ester of the above fatty acid and a polyhydric alcohol.
- the polyhydric alcohol is not particularly limited as long as it is a compound having two or more alcoholic hydroxyl groups in the molecule, and examples thereof include ethylene glycol, propylene glycol, and glycerin. That is, examples of the ester of the fatty acid and the polyhydric alcohol include ethylene glycol fatty acid ester, propylene glycol fatty acid ester, and glycerin fatty acid ester.
- ester of a fatty acid and a polyhydric alcohol is formed by ester bonding of a hydroxyl group of the polyhydric alcohol and one or more fatty acids, and the fatty acid when a plurality of hydroxyl groups are ester-bonded to the fatty acid is It may be the same or different.
- polymers such as polyethylene glycol fatty acid ester and polyglycerin fatty acid ester are not included in the ester of fatty acid and polyhydric alcohol in the present invention.
- ethylene glycol fatty acid ester examples include ethylene glycol monocaprylate, ethylene glycol dicaprylate, ethylene glycol monoisooctanoate, ethylene glycol diisooctanoate and the like.
- propylene glycol fatty acid ester examples include, in particular, propylene glycol monocaprylate (product name: Sefsol-218 manufactured by Nikko Chemicals Co., Ltd.), propylene glycol dicaprylate (product name: propylene glycol product name).
- Sefsol-228 manufactured by Nikko Chemicals Co., Ltd. propylene glycol caprylate (propylene glycolate (manufactured by Gattefosse Co., Ltd.) PGMC, etc.), propylene glycol monocaprate, propylene glycol dicaprate (product name: manufactured by Nikko Chemicals Co., Ltd.) PDD), propylene glycol monolaurate Product name: Lattelycol (registered trademark) 90 manufactured by Gattefosse, Propylene glycol dilaurate, propylene glycol laurate (Product name: Lauroglycol (registered trademark) FCC, manufactured by Gattefosse), Propylene glycol monoisooctanoate (Product name: Nikko) Chemicals (Sefsol-2126, etc.), diisooctanoic acid propylene glycol (Product name: Nikko Chemicals, Sefsol-2226), Propylene glycol myristate, Propylene glycol monostearate,
- Lutrol 2000 registered trademark
- ROPolol registered trademark
- ROPolol® registered glycol
- Propylene glycol collineate propylene glycol caprylate / caprate (propylene glycol caprylate / caprate)
- propylene glycol dicaprylate / dicaplate manufactured by propylene glycol dicaprate / dicaplate
- Product name Captex 200 manufactured by Abitec, etc.
- glycerin fatty acid ester examples include caprylic acid monoglyceride (product name: HOMOTX PT manufactured by Kao Corporation, IMWITOR 308 manufactured by SASOL Corporation, etc.), caprylic acid mono / diglyceride product (glycerol mono / dicapropyl product). Name: ISOLTOR 988 manufactured by SASOL, Capmul (registered trademark) MCM C8, etc.
- natural fats or natural lipids containing the lipophilic substances include almond oil, babas oil, borage oil, black currant seed oil, canola oil, castor oil, coconut oil, corn oil, cottonseed oil, evening primrose oil, grape seed oil , American potato oil, mustard seed oil, olive oil, palm oil, palm kernel oil, peanut oil, rapeseed oil, safflower oil, sesame oil, shark liver oil, soybean oil, sunflower oil, hydrogenated castor oil, hydrogenated coconut palm oil, hydrogenated palm oil And hardened soybean oil.
- the lipophilic substance in the present invention is preferably an ester of a fatty acid and a polyhydric alcohol, more preferably a propylene glycol fatty acid ester or a glycerin fatty acid ester, monocaprylic acid propylene glycol, dicaprylic acid propylene glycol, caprylic acid propylene glycol, caprylic acid monoglyceride, Caprylic acid mono / diglyceride, glyceryl caprylate or glyceryl tricaprylate is more preferred, and propylene glycol monocaprylate, caprylic acid monoglyceride or mono / diglyceride caprylate is particularly preferred.
- the most preferable lipophilic substance in the present invention is propylene glycol monocaprylate.
- lipophilic substances are usually produced using raw materials derived from animals and plants, their fatty acid composition is not single, but these are also preferably used for the purpose of the present invention. Moreover, in this invention, a lipophilic substance may be used individually or in mixture of 2 or more types.
- the blending amount (blending ratio) of the lipophilic substance in the composition of the present invention can be appropriately adjusted depending on the compound, but is preferably 0.01 to 100, preferably 0.1 to 20 by weight with respect to the compound. Is more preferable, and 1 to 10 is particularly preferable.
- composition of the present invention a solubilizer and / or a surfactant can be further added.
- the solubilizer in the present invention is not particularly limited as long as it improves the solubility of the present compound, and examples thereof include alcohols, amides, esters, and other solubilizers.
- examples thereof include alcohols, amides, esters, and other solubilizers.
- an ester of a fatty acid and a monohydric alcohol or a polyhydric alcohol is not included in the ester as a solubilizer.
- the monohydric alcohol or polyhydric alcohol include ethanol, anhydrous ethanol, isopropanol, anhydrous isopropanol, butanol, anhydrous butanol, benzyl alcohol, anhydrous benzyl alcohol, ethylene glycol, anhydrous ethylene glycol, propylene glycol, and anhydrous propylene.
- Glycol butanediol, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethylisosorbide, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrin and cyclodextrin derivatives .
- amide examples include 2-pyrrolidone, ⁇ -caprolactam, N-alkylpyrrolidone (including N-methylpyrrolidone), N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide, polyvinyl Examples include pyrrolidone.
- ester examples include ethyl propionate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, triethyl citrate, ethyl oleate, ethyl caprylate, ethyl butyrate, and triacetin. .
- solubilizers include dimethyl isosorbide, monooctane, acetone and the like.
- the solubilizer in the present invention is preferably a monohydric alcohol or a polyhydric alcohol, and more preferably a monohydric alcohol.
- solubilizers may be used alone or in admixture of two or more.
- the blending amount (blend ratio) of the solubilizer can be appropriately adjusted depending on the compound, but is 0.001 to 10 by weight with respect to the compound. Is preferable, 0.005 to 5 is more preferable, and 0.01 to 2 is particularly preferable.
- the surfactant in the present invention is not particularly limited as long as it improves the solubility of the present compound.
- ionic surfactants such as bile salts, phospholipids, and cationic surfactants, polyoxyethylene Alkyl ether, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyethylene glycol fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, polyoxyethylene-polyoxypropylene copolymer, polyglycerin fatty acid ester , Nonionic surfactants such as saturated polyglycolized glycerides, and other surfactants.
- bile salts as surfactants in the present invention phospholipids, cationic surfactants, polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, The polyethylene glycol fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, polyoxyethylene-polyoxypropylene copolymer, polyglycerin fatty acid ester, saturated polyglycolized glyceride and other surfactants will be described.
- bile salts include sodium cholate, sodium taurocholate, sodium glycocholate and the like.
- phospholipid examples include, in particular, purified egg yolk lecithin, purified soybean lecithin and the like.
- cationic surfactant examples include lauroyl carnitine, palmitoyl carnitine, myristoyl carnitine, and the like.
- polyoxyethylene alkyl ether examples include polyoxyethylene olein ether, polyoxyethylene stearyl ether, polyoxyethetyl ether, polyoxyethylene lauryl ether, and the like.
- polyoxyethylene sorbitan fatty acid ester examples include polysorbate 20 (product name: CRILLET 1 HP manufactured by CRODA, etc.), polysorbate 60 (product name: CRILLET 3 NF manufactured by CRODA, etc.), polysorbate 80 (product name) : CRODA manufactured by CRODA 4 HP, etc.) and polysorbate 120 (product name: CRILLET 6 manufactured by CRODA, etc.).
- polyoxyethylene sorbitol fatty acid ester examples include, in particular, polyoxyethylene sorbitol tetraoleate, polyoxyethylene sorbitol hexastearate, polyoxyethylene sorbitol monolaurate, and the like.
- polyoxyethylene castor oil examples include PEG-20 castor oil (product name: EMALEX C-20 manufactured by Nippon Emulsion Co., Ltd.), PEG-30 castor oil (product name: EMALEX C- manufactured by Nihon Emulsion Co., Ltd.). 30), polyoxyl 35 castor oil (product name: Cremophor EL, etc. manufactured by BASF), PEG-40 castor oil (product name: EMALEX C-40, manufactured by Nippon Emulsion Co., Ltd.), PEG-50 castor oil (product name: Japan) Emulex C-50 manufactured by Emulsion Co.).
- polyoxyethylene hydrogenated castor oil examples include, in particular, polyoxyethylene hydrogenated castor oil 5 (product name: Nikko Chemicals HCO-5, etc.), polyoxyethylene hydrogenated castor oil 10 (product name: Nikko Chemicals) Manufactured by HCO-10, etc.), polyoxyethylene hydrogenated castor oil 20 (product name: Nikko Chemicals HCO-20, etc.), polyoxyethylene hydrogenated castor oil 30 (product name: Nikko Chemicals HCO-30, etc.), poly Oxyethylene hydrogenated castor oil 40 (product name: Nikko Chemicals HCO-40, etc.), polyoxyethylene hydrogenated castor oil 50 (product name: Nikko Chemicals HCO-50, etc.), polyoxyethylene hydrogenated castor oil 60 (product) Name: Nikko Chemicals HCO-60, etc., polyoxyethylene hydrogenated castor oil 80 ( Name: Nikko Chemicals Inc. HCO-80, etc.), polyoxyethylene hydrogenated castor oil 100 (product name: Nikko Chemicals Inc. H
- polyethylene glycol fatty acid ester examples include polyethylene glycol monolaurate (product name: EMALEX PEL-12 manufactured by Nihon Emulsion Co., Ltd.), polyethylene glycol monooleate (product name: MYO-10V manufactured by Nikko Chemicals Co., Ltd.)
- polyethylene glycol monostearate examples include PEG-10 stearate (product name: MYS-10V manufactured by Nikko Chemicals), PEG-25 stearate, and the like.
- sucrose fatty acid ester examples include sucrose monolaurate, sucrose dilaurate, sucrose monopalmitate, sucrose dipalmitate, sucrose monostearate, sucrose distearate, Examples thereof include sucrose monooleate and sucrose dioleate.
- polyoxyethylene-polyoxypropylene copolymer examples include polyoxyethylene (150) polyoxypropylene (35) glycol (product name: Pluronic F-87, etc., manufactured by BASF), polyoxyethylene (200) polyoxy Propylene (70) glycol (product name: Pluronic F-127 manufactured by BASF), polyoxyethylene (160) polyoxypropylene (30) glycol (also referred to as Poloxamer 188) (Product name: Pluronic F-68 manufactured by BASF) ), Polyoxyethylene (20) polyoxypropylene (20) glycol (product name: Pluronic L-44, etc., manufactured by BASF), polyoxyethylene (105) polyoxypropylene (5) glycol (also referred to as PEP-101), etc. Raised Rukoto can.
- polyglycerin fatty acid ester examples include diglyceryl monostearate (product name: DGMS, manufactured by Nikko Chemicals), diglyceryl monooleate (product name: DGMO-CV, manufactured by Nikko Chemicals), monoisostearic acid, and the like.
- Diglyceryl product name: DGMIS, etc., manufactured by Nikko Chemicals
- decaglyceryl monolaurate product name: Decaglyn 1-L, etc., manufactured by Nikko Chemicals
- decaglyceryl monooleate product name: Decaglyn 1-OV, manufactured by Nikko Chemicals
- saturated polyglycolized glyceride examples include Gelucire 44/14, Gelucire 50/13, and Gelucire 53/10 (all are product names).
- surfactants include d- ⁇ -tocopherylpolyethylene glycol 1000 (product name: Vitamin E TPGS NF manufactured by Eastman).
- the surfactant in the present invention is preferably polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyglycerin fatty acid ester or d- ⁇ -tocopherylpolyethylene glycol 1000, and polyoxyethylene hydrogenated castor oil. Particularly preferred.
- the surfactants may be used alone or in combination of two or more.
- the blending amount (blending ratio) of the surfactant can be appropriately adjusted depending on the compound, but is 0.001 to 20 by weight with respect to the compound. Is preferable, 0.005 to 10 is more preferable, and 0.01 to 5 is particularly preferable.
- This compound can be formulated by using a technique commonly used as a single preparation or a combination preparation by adding a pharmaceutically acceptable additive as necessary.
- composition of the present invention can be made into capsules, powders, granules, pills, tablets or liquids by a commonly used method, and capsules are particularly preferable.
- composition of the present invention is liquid, semi-solid or solid, but as it is or as necessary, excipients such as lactose, glucose, D-mannitol, anhydrous calcium hydrogen phosphate, starch, sucrose; Disintegrants such as methylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, crospovidone, starch, partially pregelatinized starch, low-substituted hydroxypropylcellulose; hydroxypropylcellulose, ethylcellulose, gum arabic, starch, partially pregelatinized starch, polyvinylpyrrolidone Binders such as polyvinyl alcohol; lubricants such as magnesium stearate, calcium stearate, talc, hydrous silicon dioxide, hydrogenated oil; purified sucrose, hydroxypropylmethylcellulose, hydroxy Coating agents such as propyl cellulose, methyl cellulose, ethyl cellulose, polyvinyl pyrrolidone, etc .; appropriate additives such as citric acid,
- “improving intestinal absorbability” means that when the compound is administered to a patient as a solid preparation such as a tablet or liquid (including those encapsulated), it is a parent to the base of those preparations. Compared to the case where no oily substance is contained, it means that a higher intestinal absorbability of the present compound is obtained, and as a result, high bioavailability is obtained.
- the intestinal tract here means the small intestine (jejunum, duodenum, etc.), the large intestine (colon, rectum, etc.) and the like.
- AUC area under the plasma concentration-time curve
- Cmax maximum plasma concentration
- Example 2 50 parts by weight of compound A, 100 parts by weight of caprylic acid mono / diglyceride, 25 parts by weight of polyoxyethylene hydrogenated castor oil 60 (HCO-60 manufactured by Nikko Chemicals Co., Ltd.) A sample was prepared by dissolving in ethanol. In the same manner as in Example 1, a sample corresponding to 1 mg of Compound A was administered into the duodenum of rats, and then the plasma concentration transition was measured to determine AUC and Cmax.
- HCO-60 polyoxyethylene hydrogenated castor oil 60 manufactured by Nikko Chemicals Co., Ltd.
- Example 3 A sample was prepared by dissolving 50 parts by weight of Compound A in 227 parts by weight of caprylic acid mono / diglyceride, 113 parts by weight of polyoxyethylene hydrogenated castor oil 60 and 30 parts by weight of absolute ethanol. In the same manner as in Example 1, a sample corresponding to 1 mg of Compound A was administered into the duodenum of rats, and then the plasma concentration transition was measured to determine AUC and Cmax.
- Example 4 A sample was prepared by dissolving 50 parts by weight of Compound A in 150 parts by weight of propylene glycol monocaprylate (Sefsol-218 manufactured by Nikko Chemicals, the same applies hereinafter in the examples). In the same manner as in Example 1, a sample corresponding to 1 mg of Compound A was administered into the duodenum of rats, and then the plasma concentration transition was measured to determine AUC and Cmax.
- Example 5 A sample was prepared by dissolving 50 parts by weight of Compound A in 148 parts by weight of propylene glycol monocaprylate and 2 parts by weight of absolute ethanol. In the same manner as in Example 1, a sample corresponding to 1 mg of Compound A was administered into the duodenum of rats, and then the plasma concentration transition was measured to determine AUC and Cmax.
- Example 6 50 parts by weight of Compound A was mixed with 237 parts by weight of caprylic acid monoglyceride (HOMOTEX PT manufactured by Kao Corporation, the same applies hereinafter in Examples), 118 parts by weight of decaglyceryl monolaurate (Decalyn 1-L manufactured by Nikko Chemicals) and 15 parts by weight. A sample was prepared by dissolving in a portion of absolute ethanol. In the same manner as in Example 1, a sample corresponding to 1 mg of Compound A was administered into the duodenum of rats, and then the plasma concentration transition was measured to determine AUC and Cmax.
- caprylic acid monoglyceride HOMOTEX PT manufactured by Kao Corporation, the same applies hereinafter in Examples
- decaglyceryl monolaurate Decalyn 1-L manufactured by Nikko Chemicals
- composition test first liquid 15th revised Japanese Pharmacopoeia dissolution test first liquid
- a sample corresponding to 1 mg of Compound A was administered into the duodenum of rats, and then the plasma concentration transition was measured to determine AUC and Cmax.
- the first dissolution test solution can be obtained by dissolving 2.0 g of sodium chloride in 7.0 mL of hydrochloric acid and water to 1000 mL.
- Table 1 shows the blending ratios of the compositions of Examples 1 to 6 and the comparative examples, and the calculated AUC and Cmax.
- composition containing the present compound represented by Compound A and a lipophilic substance represented by propylene glycol monocaprylate, mono / diglyceryl caprylic acid or monoglyceride caprylate significantly improves the intestinal absorbability of the present compound. It is thought to improve.
- Example 7 A sample was prepared by dissolving 50 parts by weight of Compound A in 120 parts by weight of propylene glycol monocaprylate, 5 parts by weight of polyoxyethylene hydrogenated castor oil 60 and 25 parts by weight of absolute ethanol.
- LC-MS / MS high performance liquid chromatograph / mass spectrometer
- Example 8 A sample was prepared by dissolving 50 parts by weight of Compound A in 100 parts by weight of propylene glycol monocaprylate, 25 parts by weight of polyoxyethylene hydrogenated castor oil 60 and 25 parts by weight of absolute ethanol. In the same manner as in Example 7, a sample corresponding to 1 mg of compound A was administered into the jejunum of rats, and then plasma concentration transitions were measured to determine AUC and Cmax.
- Example 9 50 parts by weight of compound A was dissolved in 100 parts by weight of propylene glycol monocaprylate, 25 parts by weight of polysorbate 80 (CRILLET 4 HP manufactured by CRODA, the same applies hereinafter in the examples) and 25 parts by weight of absolute ethanol, and a sample was prepared.
- a sample corresponding to 1 mg of compound A was administered into the jejunum of rats, and then plasma concentration transitions were measured to determine AUC and Cmax.
- Example 10 50 parts by weight of compound A was dissolved in 100 parts by weight of propylene glycol monocaprylate, 25 parts by weight of polyoxyl 35 castor oil (Cremophor EL manufactured by BASF) and 25 parts by weight of absolute ethanol to prepare a sample. In the same manner as in Example 7, a sample corresponding to 1 mg of compound A was administered into the jejunum of rats, and then plasma concentration transitions were measured to determine AUC and Cmax.
- Example 11 A sample was prepared by dissolving 50 parts by weight of Compound A in 125 parts by weight of caprylic acid monoglyceride and 25 parts by weight of absolute ethanol. In the same manner as in Example 7, a sample corresponding to 1 mg of compound A was administered into the jejunum of rats, and then plasma concentration transitions were measured to determine AUC and Cmax.
- Example 12 A sample was prepared by dissolving 50 parts by weight of Compound A in 100 parts by weight of caprylic acid monoglyceride, 25 parts by weight of polyoxyl 35 castor oil and 25 parts by weight of absolute ethanol. In the same manner as in Example 7, a sample corresponding to 1 mg of compound A was administered into the jejunum of rats, and then plasma concentration transitions were measured to determine AUC and Cmax.
- Table 2 shows the blending ratios of the compositions of Examples 7 to 12 and the calculated AUC and Cmax.
- composition containing the present compound represented by Compound A and the lipophilic substance represented by propylene glycol monocaprylate or monoglyceride caprylate is considered to significantly improve the intestinal absorbability of the present compound. .
- Example 13 to 15 When the composition of the present invention was filled in a capsule and orally administered to a dog, the blood transferability of the present compound was examined.
- Example 13 A sample was prepared by dissolving 50 parts by weight of Compound A in 227 parts by weight of caprylic acid mono / diglyceride, 113 parts by weight of polyoxyethylene hydrogenated castor oil 60 and 30 parts by weight of absolute ethanol.
- LC-MS / MS high performance liquid chromatograph / mass spectrometer
- Example 14 A sample was prepared by dissolving 75 parts by weight of Compound A in 203 parts by weight of caprylic acid mono / diglyceride, 102 parts by weight of polyoxyethylene hydrogenated castor oil 60 and 40 parts by weight of absolute ethanol. In the same manner as in Example 13, a sample corresponding to 20 mg of Compound A was filled in a capsule and orally administered to a dog. Then, the plasma concentration transition was measured to determine AUC and Cmax.
- Example 15 A sample was prepared by dissolving 50 parts by weight of Compound A in 237 parts by weight of caprylic acid monoglyceride, 118 parts by weight of decaglyceryl monolaurate and 15 parts by weight of absolute ethanol. In the same manner as in Example 13, a sample corresponding to 20 mg of Compound A was filled in a capsule and orally administered to a dog. Then, the plasma concentration transition was measured to determine AUC and Cmax.
- Table 3 shows the AUC and Cmax determined in Examples 13 to 15 above.
- composition containing the present compound typified by Compound A and a lipophilic substance typified by caprylic acid mono / diglyceride or caprylic acid monoglyceride when these are filled in capsules and administered orally, It is considered that the intestinal absorbability of this compound is remarkably improved.
- Capsule (Content: 200mg) Compound A 50mg Propylene glycol monocaprylate 148mg Absolute ethanol 2mg Capsules can be obtained by filling capsules with a solution obtained by mixing the above components. Desired capsules having different internal contents of Compound A can also be obtained by appropriately changing the amount of Compound A and the kind and / or amount of additives.
- Formulation Example 3 Tablet (in 200 mg) Compound A 50mg Propylene glycol monocaprylate 2mg Lactose 95mg Corn starch 40mg Carboxymethylcellulose calcium 6mg Hydroxypropylcellulose 6mg Magnesium stearate 1mg
- a tablet of the above formulation can be coated with 3 mg of a coating agent (for example, a coating agent such as hydroxypropylmethylcellulose, macrogol, talc, titanium oxide, silicone resin) to obtain the intended tablet.
- a coating agent for example, a coating agent such as hydroxypropylmethylcellulose, macrogol, talc, titanium oxide, silicone resin
- the desired tablet from which the internal volume of compound A differs can also be obtained by changing suitably the quantity of compound A, and the kind and / or quantity of an additive.
- the present invention is useful as providing a pharmaceutical composition that improves the intestinal absorbability of the present compound.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
Description
また、本発明の他の態様は、(a)以下の群から選ばれる少なくとも1つの化合物又はその塩、及び(b)親油性物質を含有する医薬組成物である。
・1-[2-(1-アダマンチル)エチル]-3-[3-(4-ピリジル)プロピル]-1-(3,3,3-トリフルオロプロピル)ウレア、
・1-[2-(1-アダマンチル)エチル]-1-(2-ブテニル)-3-[3-(4-ピリジル)プロピル]ウレア、
・1-[2-(1-アダマンチル)エチル]-1-[2-[N-(t-ブトキシカルボニル)-N-メチルアミノ]エチル]-3-[3-(4-ピリジル)プロピル]ウレア、
・1-[3-(1-アダマンチル)プロピル]-1-プロピル-3-[3-(4-ピリジル)プロピル]ウレア、
・(Z)-1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[3-(4-ピリジル)-2-プロペニル]ウレア、
・(-)-1-[2-(1-アダマンチル)エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]-1-ペンチルウレア、
・1-[2-(1-アダマンチル)エチル]-3-[1-メチル-3-(4-ピリジル)プロピル]-1-ペンチルウレア、
・(+)-1-[2-(1-アダマンチル)エチル]-1-[2-[N-(t-ブトキシカルボニル)-N-メチルアミノ]エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]ウレア、
・5-(4-ピリジル)吉草酸 N-[2-(1-アダマンチル)エチル]-N-ペンチルアミド、
・3-(4-ピリジルメチルチオ)プロピオン酸 N-[2-(1-アダマンチル)エチル]-N-ペンチルアミド、
・2-[2-(4-ピリジル)エチルチオ]酢酸 N-[2-(1-アダマンチル)エチル]-N-ペンチルアミド、
・6-(4-ピリジル)カプロン酸 N-[2-(1-アダマンチル)エチル]-N-ペンチルアミド、
・cis-1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[2-(4-ピリジル)シクロプロピルメチル]ウレア、
・1-[2-(1-アダマンチル)エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]-1-ペンチルウレア、
・1-[2-(1-アダマンチル)エチル]-1-[2-[N-(t-ブトキシカルボニル)-N-メチルアミノ]エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]ウレア
・(E)-1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[3-(4-ピリジル)-2-プロペニル]ウレアおよび
・(+)-1-[2-(1-アダマンチル)エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]-1-ペンチルウレア。
1)R2:アダマンチルアルキル基。
B:鎖中に、-S-若しくは
R1:アルキル基又はアルケニル基であって、該アルキル基及びアルケニル基はハロゲン原子又はアミノ基で置換されていてもよく、さらに該アミノ基はアルキル基、アシル基、アルコキシカルボニル基又はシクロアルキルオキシカルボニル基で置換されていてもよい、
R2:アダマンチルアルキル基、
R3:ピリジン環、
R4:水素原子、
R5及びR6:水素原子、
X:酸素原子、
n:1。
B:プロピレン基、1-メチルプロパン-1,3-ジイル基、2-メチルプロパン-1,3-ジイル基、-CH2-S-CH2-、-S-CH2CH2-、ブタン-1,4-ジイル基、ビニレン基、プロペン-1,3-ジイル基又は
R2:アダマンチルエチル基又はアダマンチルプロピル基、
R3:ピリジン環、
X:酸素原子。
本発明の組成物をラット十二指腸内投与した場合の本化合物の血中移行性を検討した。
50重量部の化合物Aを、150重量部のカプリル酸モノ/ジグリセリド(SASOL社製 IMWITOR 988、実施例において以下同じ)に溶解し、試料を調製した。次に、化合物A 1mgに相当する量の試料を、針付注射筒を用いて非絶食ラット(SD系雄性ラット、n=3)の十二指腸内に投与した。投与後、0.25、0.5、1、2、4及び6時間に血液を採取し、得られた血漿中の化合物Aの濃度を高速液体クロマトグラフ/質量分析計(LC-MS/MS)により測定した。得られた化合物Aの血漿中濃度推移から、血漿中濃度-時間曲線下面積(AUC)及び最大血漿中濃度(Cmax)を算出した。
50重量部の化合物Aを、100重量部のカプリル酸モノ/ジグリセリド、25重量部のポリオキシエチレン硬化ヒマシ油60(日光ケミカルズ社製 HCO-60、実施例において以下同じ)及び25重量部の無水エタノールに溶解し、試料を調製した。実施例1と同様の方法にて、化合物A 1mgに相当する量の試料をラットの十二指腸内に投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。
50重量部の化合物Aを、227重量部のカプリル酸モノ/ジグリセリド、113重量部のポリオキシエチレン硬化ヒマシ油60及び30重量部の無水エタノールに溶解し、試料を調製した。実施例1と同様の方法にて、化合物A 1mgに相当する量の試料をラットの十二指腸内に投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。
50重量部の化合物Aを、150重量部のモノカプリル酸プロピレングリコール(日光ケミカルズ社製 Sefsol-218、実施例において以下同じ)に溶解し、試料を調製した。実施例1と同様の方法にて、化合物A 1mgに相当する量の試料をラットの十二指腸内に投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。
50重量部の化合物Aを、148重量部のモノカプリル酸プロピレングリコール及び2重量部の無水エタノールに溶解し、試料を調製した。実施例1と同様の方法にて、化合物A 1mgに相当する量の試料をラットの十二指腸内に投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。
50重量部の化合物Aを、237重量部のカプリル酸モノグリセリド(花王社製 HOMOTEX PT、実施例において以下同じ)、118重量部のモノラウリン酸デカグリセリル(日光ケミカルズ社製 Decaglyn 1-L)及び15重量部の無水エタノールに溶解し、試料を調製した。実施例1と同様の方法にて、化合物A 1mgに相当する量の試料をラットの十二指腸内に投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。
10重量部の化合物Aを、1000重量部の第十五改正日本薬局方 溶出試験第1液(以下、「溶出試験第1液」という)に懸濁し、試料を調製した。次に、化合物A 1mgに相当する量の試料を、針付注射筒を用いて非絶食ラット(SD系雄性ラット、n=3)の十二指腸内に投与した。実施例1と同様の方法にて、化合物A 1mgに相当する量の試料をラットの十二指腸内に投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。なお、溶出試験第1液は、塩化ナトリウム 2.0gを塩酸 7.0mL及び水に溶かして1000mLとすることで得ることができる。
本発明の組成物をラット空腸内投与した場合の本化合物の血中移行性を検討した。
50重量部の化合物Aを、120重量部のモノカプリル酸プロピレングリコール、5重量部のポリオキシエチレン硬化ヒマシ油60及び25重量部の無水エタノールに溶解し、試料を調製した。化合物A 1mgに相当する量の試料を、針付注射筒を用いて一晩絶食したラット(SD系雄性ラット、n=3)の空腸内に投与した。投与後、0.25、0.5、1、2、4及び6時間に血液を採取し、得られた血漿中の化合物Aの濃度を高速液体クロマトグラフ/質量分析計(LC-MS/MS)により測定した。得られた化合物Aの血漿中濃度推移から、AUC及びCmaxを算出した。
50重量部の化合物Aを、100重量部のモノカプリル酸プロピレングリコール、25重量部のポリオキシエチレン硬化ヒマシ油60及び25重量部の無水エタノールに溶解し、試料を調製した。実施例7と同様の方法にて、化合物A 1mgに相当する量の試料をラットの空腸内に投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。
50重量部の化合物Aを、100重量部のモノカプリル酸プロピレングリコール、25重量部のポリソルベート80(CRODA社製 CRILLET 4 HP、実施例において以下同じ)及び25重量部の無水エタノールに溶解し、試料を調製した。実施例7と同様の方法にて、化合物A 1mgに相当する量の試料をラットの空腸内に投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。
50重量部の化合物Aを、100重量部のモノカプリル酸プロピレングリコール、25重量部のポリオキシル35ヒマシ油(BASF社製 Cremophor EL)及び25重量部の無水エタノールに溶解し、試料を調製した。実施例7と同様の方法にて、化合物A 1mgに相当する量の試料をラットの空腸内に投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。
50重量部の化合物Aを、125重量部のカプリル酸モノグリセリド及び25重量部の無水エタノールに溶解し、試料を調製した。実施例7と同様の方法にて、化合物A 1mgに相当する量の試料をラットの空腸内に投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。
50重量部の化合物Aを、100重量部のカプリル酸モノグリセリド、25重量部のポリオキシル35ヒマシ油及び25重量部の無水エタノールに溶解し、試料を調製した。実施例7と同様の方法にて、化合物A 1mgに相当する量の試料をラットの空腸内に投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。
本発明の組成物をカプセルに充填し、イヌに経口投与した場合の本化合物の血中移行性を検討した。
50重量部の化合物Aを、227重量部のカプリル酸モノ/ジグリセリド、113重量部のポリオキシエチレン硬化ヒマシ油60及び30重量部の無水エタノールに溶解し、試料を調製した。化合物A 20mgに相当する量の試料をゼラチンハードカプセル(クオリカプスカプセル、1号)に充填した後、一晩絶食したイヌ(雄性ビーグル、n=1)に経口投与した。投与後、0.5、1、2、4、6、8及び24時間に血液を採取し、得られた血漿中の化合物Aの濃度を高速液体クロマトグラフ/質量分析計(LC-MS/MS)により測定した。得られた化合物Aの血漿中濃度推移から、AUC及びCmaxを算出した。
75重量部の化合物Aを、203重量部のカプリル酸モノ/ジグリセリド、102重量部のポリオキシエチレン硬化ヒマシ油60及び40重量部の無水エタノールに溶解し、試料を調製した。実施例13と同様の方法にて、化合物A 20mgに相当する量の試料をカプセルに充填し、イヌに経口投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。
50重量部の化合物Aを、237重量部のカプリル酸モノグリセリド、118重量部のモノラウリン酸デカグリセリル及び15重量部の無水エタノールに溶解し、試料を調製した。実施例13と同様の方法にて、化合物A 20mgに相当する量の試料をカプセルに充填し、イヌに経口投与した後、血漿中濃度推移を測定し、AUC及びCmaxを求めた。
製剤例を挙げて本発明をさらに具体的に説明するが、本発明はこれらの製剤例にのみ限定されるものではない。
化合物A 50mg
モノカプリル酸プロピレングリコール 148mg
無水エタノール 2mg
上記成分を混合して得られた溶液をカプセルに充填することで、カプセル剤を得ることができる。化合物Aの量、並びに添加剤の種類及び/又は量を適宜変更することで、化合物Aの内容量の異なる所望のカプセル剤を得ることもできる。
化合物A 25mg
カプリル酸モノ/ジグリセリド 113.5mg
ポリオキシエチレン硬化ヒマシ油60 56.5mg
無水エタノール 15mg
化合物Aの量、並びに添加剤の種類及び/又は量を適宜変更することで、化合物Aの内容量の異なる所望の液剤を得ることもできる。
化合物A 50mg
モノカプリル酸プロピレングリコール 2mg
乳糖 95mg
トウモロコシデンプン 40mg
カルボキシメチルセルロースカルシウム 6mg
ヒドロキシプロピルセルロース 6mg
ステアリン酸マグネシウム 1mg
上記処方の錠剤にコーティング剤(例えば、ヒドロキシプロピルメチルセルロース、マクロゴール、タルク、酸化チタン、シリコーン樹脂等のコーティング剤)3mgを用いてコーティングを施し、目的とする錠剤を得ることができる。また、化合物Aの量、並びに添加物の種類及び/又は量を適宜変更することで、化合物Aの内容量の異なる所望の錠剤を得ることもできる。
Claims (23)
- (a)下記一般式[1]で表される化合物又はその塩、及び(b)親油性物質を含有する医薬組成物。
- R2がアダマンチルアルキル基を示し、R3がピリジン環を示す、請求項1記載の組成物。
- 一般式[1]で表される化合物又はその塩が、
・1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[3-(4-ピリジル)プロピル]ウレア、
・1-[2-(1-アダマンチル)エチル]-3-[3-(4-ピリジル)プロピル]-1-(3,3,3-トリフルオロプロピル)ウレア、
・1-[2-(1-アダマンチル)エチル]-1-(2-ブテニル)-3-[3-(4-ピリジル)プロピル]ウレア、
・1-[2-(1-アダマンチル)エチル]-1-[2-[N-(t-ブトキシカルボニル)-N-メチルアミノ]エチル]-3-[3-(4-ピリジル)プロピル]ウレア、
・1-[3-(1-アダマンチル)プロピル]-1-プロピル-3-[3-(4-ピリジル)プロピル]ウレア、
・(Z)-1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[3-(4-ピリジル)-2-プロペニル]ウレア、
・(-)-1-[2-(1-アダマンチル)エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]-1-ペンチルウレア、
・1-[2-(1-アダマンチル)エチル]-3-[1-メチル-3-(4-ピリジル)プロピル]-1-ペンチルウレア、
・(+)-1-[2-(1-アダマンチル)エチル]-1-[2-[N-(t-ブトキシカルボニル)-N-メチルアミノ]エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]ウレア、
・5-(4-ピリジル)吉草酸 N-[2-(1-アダマンチル)エチル]-N-ペンチルアミド、
・3-(4-ピリジルメチルチオ)プロピオン酸 N-[2-(1-アダマンチル)エチル]-N-ペンチルアミド、
・2-[2-(4-ピリジル)エチルチオ]酢酸 N-[2-(1-アダマンチル)エチル]-N-ペンチルアミド、
・6-(4-ピリジル)カプロン酸 N-[2-(1-アダマンチル)エチル]-N-ペンチルアミド、
・cis-1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[2-(4-ピリジル)シクロプロピルメチル]ウレア、
・1-[2-(1-アダマンチル)エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]-1-ペンチルウレア、
・1-[2-(1-アダマンチル)エチル]-1-[2-[N-(t-ブトキシカルボニル)-N-メチルアミノ]エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]ウレア、
・(E)-1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[3-(4-ピリジル)-2-プロペニル]ウレアおよび
・(+)-1-[2-(1-アダマンチル)エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]-1-ペンチルウレア
よりなる群から選ばれる少なくとも1つの化合物又はその塩である、請求項1記載の組成物。 - (a)1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[3-(4-ピリジル)プロピル]ウレア又はその塩、及び(b)親油性物質を含有する医薬組成物。
- 該親油性物質が、プロピレングリコール脂肪酸エステル及び/又はグリセリン脂肪酸エステルである、請求項1~5記載の組成物。
- 該親油性物質が、モノカプリル酸プロピレングリコール、カプリル酸モノグリセリド及びカプリル酸モノ/ジグリセリドからなる群から選ばれる少なくとも1種である、請求項5記載の組成物。
- 該親油性物質が、モノカプリル酸プロピレングリコールである、請求項5記載の組成物。
- 可溶化剤及び/又は界面活性剤を含有する、請求項7記載の組成物。
- 患者に、(a)下記一般式[1]で表される化合物又はその塩、及び(b)親油性物質を含有する医薬組成物を投与することからなる、該化合物又はその塩の腸管吸収性を改善する方法。
- R2がアダマンチルアルキル基を示し、R3がピリジン環を示す、請求項10記載の方法。
- Aが-(NR4)-又は-(CR5R6)-を示し;Bが鎖中に-S-若しくは
- 一般式[1]で表される化合物又はその塩が、
・1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[3-(4-ピリジル)プロピル]ウレア、
・1-[2-(1-アダマンチル)エチル]-3-[3-(4-ピリジル)プロピル]-1-(3,3,3-トリフルオロプロピル)ウレア、
・1-[2-(1-アダマンチル)エチル]-1-(2-ブテニル)-3-[3-(4-ピリジル)プロピル]ウレア、
・1-[2-(1-アダマンチル)エチル]-1-[2-[N-(t-ブトキシカルボニル)-N-メチルアミノ]エチル]-3-[3-(4-ピリジル)プロピル]ウレア、
・1-[3-(1-アダマンチル)プロピル]-1-プロピル-3-[3-(4-ピリジル)プロピル]ウレア、
・(Z)-1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[3-(4-ピリジル)-2-プロペニル]ウレア、
・(-)-1-[2-(1-アダマンチル)エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]-1-ペンチルウレア、
・1-[2-(1-アダマンチル)エチル]-3-[1-メチル-3-(4-ピリジル)プロピル]-1-ペンチルウレア、
・(+)-1-[2-(1-アダマンチル)エチル]-1-[2-[N-(t-ブトキシカルボニル)-N-メチルアミノ]エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]ウレア、
・5-(4-ピリジル)吉草酸 N-[2-(1-アダマンチル)エチル]-N-ペンチルアミド、
・3-(4-ピリジルメチルチオ)プロピオン酸 N-[2-(1-アダマンチル)エチル]-N-ペンチルアミド、
・2-[2-(4-ピリジル)エチルチオ]酢酸 N-[2-(1-アダマンチル)エチル]-N-ペンチルアミド、
・6-(4-ピリジル)カプロン酸 N-[2-(1-アダマンチル)エチル]-N-ペンチルアミド、
・cis-1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[2-(4-ピリジル)シクロプロピルメチル]ウレア、
・1-[2-(1-アダマンチル)エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]-1-ペンチルウレア、
・1-[2-(1-アダマンチル)エチル]-1-[2-[N-(t-ブトキシカルボニル)-N-メチルアミノ]エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]ウレア、
・(E)-1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[3-(4-ピリジル)-2-プロペニル]ウレアおよび
・(+)-1-[2-(1-アダマンチル)エチル]-3-[2-メチル-3-(4-ピリジル)プロピル]-1-ペンチルウレア
よりなる群から選ばれる少なくとも1つの化合物又はその塩である、請求項10記載の方法。 - 患者に、(a)1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[3-(4-ピリジル)プロピル]ウレア又はその塩、及び(b)親油性物質を含有する医薬組成物を投与することからなる、1-[2-(1-アダマンチル)エチル]-1-ペンチル-3-[3-(4-ピリジル)プロピル]ウレア又はその塩の腸管吸収性を改善する方法。
- 該親油性物質が、プロピレングリコール脂肪酸エステル及び/又はグリセリン脂肪酸エステルである、請求項10~14記載の方法。
- 該親油性物質が、モノカプリル酸プロピレングリコール、カプリル酸モノグリセリド及びカプリル酸モノ/ジグリセリドからなる群から選ばれる少なくとも1種である、請求項14記載の方法。
- 該親油性物質が、モノカプリル酸プロピレングリコールである、請求項14記載の方法。
- 該医薬組成物が、可溶化剤及び/又は界面活性剤を含有する、請求項16記載の方法。
- 請求項1~5記載の医薬組成物を製造するための一般式[1]で表される化合物又はその塩の使用。
- 該親油性物質が、プロピレングリコール脂肪酸エステル及び/又はグリセリン脂肪酸エステルである、請求項19記載の使用。
- 該親油性物質が、モノカプリル酸プロピレングリコール、カプリル酸モノグリセリド及びカプリル酸モノ/ジグリセリドからなる群から選ばれる少なくとも1種である、請求項19記載の使用。
- 該親油性物質が、モノカプリル酸プロピレングリコールである、請求項19記載の使用。
- 該医薬組成物が、可溶化剤及び/又は界面活性剤を含有する、請求項21記載の使用。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/124,797 US8686006B2 (en) | 2008-10-22 | 2009-10-22 | Pharmaceutical composition for improving intestinal absorption |
KR1020117011240A KR101702142B1 (ko) | 2008-10-22 | 2009-10-22 | 장관 흡수성을 개선하는 의약 조성물 |
ES09822058.5T ES2528421T3 (es) | 2008-10-22 | 2009-10-22 | Composición farmacéutica de mejor absorción a través del tracto intestinal |
PL09822058T PL2351566T3 (pl) | 2008-10-22 | 2009-10-22 | Kompozycja farmaceutyczna o ulepszonym wchłanianiu przez układ pokarmowy |
CA2739882A CA2739882A1 (en) | 2008-10-22 | 2009-10-22 | Pharmaceutical composition improving intestinal absorption |
EP09822058.5A EP2351566B1 (en) | 2008-10-22 | 2009-10-22 | Pharmaceutical composition improved in absorption through intestinal tract |
CN2009801419946A CN102196810B (zh) | 2008-10-22 | 2009-10-22 | 改善肠吸收性的药物组合物 |
BRPI0919858A BRPI0919858A2 (pt) | 2008-10-22 | 2009-10-22 | Composição farmacêutica, método para melhorar a absorção intestinal, e uso de um composto representado pela fórmula geral (1) ou um sal do mesmo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008271948 | 2008-10-22 | ||
JP2008-271948 | 2008-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010047361A1 true WO2010047361A1 (ja) | 2010-04-29 |
Family
ID=42119398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/068164 WO2010047361A1 (ja) | 2008-10-22 | 2009-10-22 | 腸管吸収性を改善する医薬組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8686006B2 (ja) |
EP (1) | EP2351566B1 (ja) |
JP (1) | JP5613396B2 (ja) |
KR (1) | KR101702142B1 (ja) |
CN (1) | CN102196810B (ja) |
BR (1) | BRPI0919858A2 (ja) |
CA (1) | CA2739882A1 (ja) |
ES (1) | ES2528421T3 (ja) |
PL (1) | PL2351566T3 (ja) |
WO (1) | WO2010047361A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110382006A (zh) * | 2017-03-03 | 2019-10-25 | 株式会社Moresco | 吸收促进剂及其应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691808B2 (en) | 2011-05-20 | 2014-04-08 | Influmedix, Inc. | Antiviral compounds and their methods of use |
WO2014087931A1 (ja) | 2012-12-04 | 2014-06-12 | ロート製薬株式会社 | 水性眼科組成物 |
WO2020203733A1 (ja) * | 2019-03-29 | 2020-10-08 | 積水化学工業株式会社 | コアシェル構造体、製剤、外用薬、テープ剤及び化粧品 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10503750A (ja) * | 1994-03-16 | 1998-04-07 | アール. ピー. シェーラー リミテッド | 疎水性薬剤の投与システム |
JP2000510458A (ja) * | 1996-04-26 | 2000-08-15 | アール.ピー.シェーラー リミテッド | 医薬用組成物 |
JP2002053555A (ja) | 2000-05-31 | 2002-02-19 | Santen Pharmaceut Co Ltd | TNF−α産生阻害物質 |
JP2003226686A (ja) | 2001-11-30 | 2003-08-12 | Santen Pharmaceut Co Ltd | 血管新生阻害剤 |
JP2005336174A (ja) | 2004-04-27 | 2005-12-08 | Santen Pharmaceut Co Ltd | 変形性関節症治療剤 |
JP2005336173A (ja) | 2004-04-27 | 2005-12-08 | Santen Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JP2006117654A (ja) | 2004-09-27 | 2006-05-11 | Santen Pharmaceut Co Ltd | 呼吸器疾患治療剤 |
JP2006117653A (ja) | 2004-09-27 | 2006-05-11 | Santen Pharmaceut Co Ltd | 皮膚疾患治療剤 |
JP2006143707A (ja) | 2004-10-18 | 2006-06-08 | Santen Pharmaceut Co Ltd | 神経疾患治療剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037057A2 (en) * | 1998-12-18 | 2000-06-29 | Abbott Laboratories | Novel formulations comprising lipid-regulating agents |
AU1043201A (en) * | 1999-11-02 | 2001-05-14 | Cipla Limited | Cyclosporin formulation |
WO2003045367A1 (fr) * | 2001-11-30 | 2003-06-05 | Santen Pharmaceutical Co., Ltd. | Inhibiteur d'angiogenese |
WO2005102331A1 (ja) | 2004-04-27 | 2005-11-03 | Santen Pharmaceutical Co., Ltd. | 骨粗鬆症治療剤 |
WO2006035760A1 (ja) | 2004-09-27 | 2006-04-06 | Santen Pharmaceutical Co., Ltd. | 皮膚疾患治療剤 |
WO2006035759A1 (ja) | 2004-09-27 | 2006-04-06 | Santen Pharmaceutical Co., Ltd. | 呼吸器疾患治療剤 |
WO2006043518A1 (ja) | 2004-10-18 | 2006-04-27 | Santen Pharmaceutical Co., Ltd. | 神経疾患治療剤 |
JP5406529B2 (ja) * | 2005-10-26 | 2014-02-05 | バナー ファーマキャプス, インコーポレイテッド | カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム |
-
2009
- 2009-10-22 CN CN2009801419946A patent/CN102196810B/zh not_active Expired - Fee Related
- 2009-10-22 US US13/124,797 patent/US8686006B2/en not_active Expired - Fee Related
- 2009-10-22 BR BRPI0919858A patent/BRPI0919858A2/pt not_active IP Right Cessation
- 2009-10-22 CA CA2739882A patent/CA2739882A1/en not_active Abandoned
- 2009-10-22 JP JP2009242956A patent/JP5613396B2/ja active Active
- 2009-10-22 WO PCT/JP2009/068164 patent/WO2010047361A1/ja active Application Filing
- 2009-10-22 ES ES09822058.5T patent/ES2528421T3/es active Active
- 2009-10-22 KR KR1020117011240A patent/KR101702142B1/ko active IP Right Grant
- 2009-10-22 PL PL09822058T patent/PL2351566T3/pl unknown
- 2009-10-22 EP EP09822058.5A patent/EP2351566B1/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10503750A (ja) * | 1994-03-16 | 1998-04-07 | アール. ピー. シェーラー リミテッド | 疎水性薬剤の投与システム |
JP2000510458A (ja) * | 1996-04-26 | 2000-08-15 | アール.ピー.シェーラー リミテッド | 医薬用組成物 |
JP2002053555A (ja) | 2000-05-31 | 2002-02-19 | Santen Pharmaceut Co Ltd | TNF−α産生阻害物質 |
JP2003226686A (ja) | 2001-11-30 | 2003-08-12 | Santen Pharmaceut Co Ltd | 血管新生阻害剤 |
JP2005336174A (ja) | 2004-04-27 | 2005-12-08 | Santen Pharmaceut Co Ltd | 変形性関節症治療剤 |
JP2005336173A (ja) | 2004-04-27 | 2005-12-08 | Santen Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JP2006117654A (ja) | 2004-09-27 | 2006-05-11 | Santen Pharmaceut Co Ltd | 呼吸器疾患治療剤 |
JP2006117653A (ja) | 2004-09-27 | 2006-05-11 | Santen Pharmaceut Co Ltd | 皮膚疾患治療剤 |
JP2006143707A (ja) | 2004-10-18 | 2006-06-08 | Santen Pharmaceut Co Ltd | 神経疾患治療剤 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110382006A (zh) * | 2017-03-03 | 2019-10-25 | 株式会社Moresco | 吸收促进剂及其应用 |
CN110382006B (zh) * | 2017-03-03 | 2023-03-24 | 株式会社Moresco | 吸收促进剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US8686006B2 (en) | 2014-04-01 |
EP2351566A1 (en) | 2011-08-03 |
EP2351566A4 (en) | 2013-05-22 |
JP2010120930A (ja) | 2010-06-03 |
US20110201655A1 (en) | 2011-08-18 |
JP5613396B2 (ja) | 2014-10-22 |
BRPI0919858A2 (pt) | 2017-08-15 |
CN102196810B (zh) | 2013-11-06 |
PL2351566T3 (pl) | 2015-06-30 |
CN102196810A (zh) | 2011-09-21 |
ES2528421T3 (es) | 2015-02-09 |
KR20110073583A (ko) | 2011-06-29 |
EP2351566B1 (en) | 2014-12-10 |
CA2739882A1 (en) | 2010-04-29 |
KR101702142B1 (ko) | 2017-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101716878B1 (ko) | 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법 | |
JP2006501134A (ja) | 高い生物学的利用能を有する、経口活性タキサン誘導体の医薬組成物 | |
JP2022084651A (ja) | 新規組成物および方法 | |
WO2006134864A1 (ja) | 可溶化型製剤 | |
US11116744B2 (en) | Pharmaceutical composition for oral administration comprising taxane | |
KR101976137B1 (ko) | 두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법 | |
JP5613396B2 (ja) | 腸管吸収性を改善する医薬組成物 | |
KR101767296B1 (ko) | 활성제로서 페닐아미노피리미딘 유도체를 포함하는 제제 | |
JP7314459B2 (ja) | 3α-エチニル-3β-ヒドロキシアンドロスタン-17-オンオキシムの医薬製剤 | |
KR20180041704A (ko) | 제약 제제 | |
KR101996597B1 (ko) | 두타스테리드와 타다라필을 용해시킨 경구용 캡슐 제형의 복합제제 | |
KR100712823B1 (ko) | 가용성 코엔자임 큐10의 연질캡슐제 조성물 및 그의제조방법 | |
KR20130109570A (ko) | 레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물 | |
KR101612255B1 (ko) | 고농도의 탁산을 포함하는 경구 투여용 약학 조성물 | |
JP2948111B2 (ja) | 経口投与用油性組成物 | |
JP5936609B2 (ja) | キナーゼインヒビターの経口製剤 | |
WO2022150561A1 (en) | Stable solutions of immunomodulatory imide compounds for parenteral use | |
US10987335B2 (en) | Pharmaceutical composition for oral administration comprising high concentration taxane | |
CN114344309B (zh) | 一种别孕烷醇酮衍生物自乳化制剂及其制备方法 | |
KR102185475B1 (ko) | 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물 | |
WO2017011445A1 (en) | Heteroaryl carbonitriles for the treatment of disease | |
KR101612260B1 (ko) | 고농도의 탁산을 포함하는 경구 투여용 약학 조성물 | |
KR20220124891A (ko) | 나파모스타트 또는 이의 염을 포함하는 에멀젼을 포함하는 약제학적 제제 및 이의 제조 방법 | |
EA010293B1 (ru) | Частицеобразующие композиции, содержащие конденсированные пирролокарбазолы | |
EP2228055A1 (en) | Riluzole liquid emulsions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980141994.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09822058 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2739882 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009822058 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13124797 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20117011240 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
ENP | Entry into the national phase |
Ref document number: PI0919858 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110419 |